IsoRay, Inc. (DE) (ISR): Price and Financial Metrics

IsoRay, Inc. (DE) (ISR)

Today's Latest Price: $0.70 USD

0.01 (-1.63%)

Updated Jun 4 4:10pm

Add ISR to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 304 in Miscellaneous

See all "A" rated Strong Buy stocks

ISR Stock Summary

  • ISR has a market capitalization of $48,505,442 -- more than approximately just 16.25% of US stocks.
  • For ISR, its debt to operating expenses ratio is greater than that reported by merely 12.81% of US equities we're observing.
  • As for revenue growth, note that ISR's revenue has grown 33.35% over the past 12 months; that beats the revenue growth of 85.52% of US companies in our set.
  • Stocks that are quantitatively similar to ISR, based on their financial statements, market capitalization, and price volatility, are IRIX, SPNE, JT, AXGN, and HEAR.
  • Visit ISR's SEC page to see the company's official filings. To visit the company's web site, go to
ISR Daily Price Range
ISR 52-Week Price Range

ISR Stock Price Chart More Charts

ISR Price/Volume Stats

Current price $0.70 52-week high $1.06
Prev. close $0.72 52-week low $0.29
Day low $0.69 Volume 461,187
Day high $0.72 Avg. volume 581,220
50-day MA $0.63 Dividend yield N/A
200-day MA $0.57 Market Cap 47.69M

ISR Latest News Stream

Event/TimeNews Detail
Loading, please wait...

ISR Latest Social Stream

Loading social stream, please wait...

View Full ISR Social Stream

Latest ISR News From Around the Web

Below are the latest news stories about Isoray Inc that investors may wish to consider to help them evaluate ISR as an investment opportunity.

IsoRay (ISR) Upgraded to Buy: What Does It Mean for the Stock?

IsoRay (ISR) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | June 4, 2020

Second Ten Year Data Report Demonstrates Efficacy of Isoray’s Cesium-131 Internal Radiation Therapy in the Treatment of Prostate Cancer

Isoray, Inc. (NYSE American: ISR) today announced that the results of a new ten year study show positive outcomes for low-risk and intermediate-risk prostate cancer patients treated with Isoray’s Cesium-131 (Cesium Blu) internal radiation therapy (brachytherapy). The observational study from the University of Pittsburgh School of Medicine followed a large group of patients for up to ten years. Patients with higher risk cancers were treated with external beam radiation therapy in addition to their Cesium-131 implant, while lower risk patients underwent only a Cesium-131 implant.

Yahoo | June 2, 2020

Company News for May 14, 2020

Companies In The News Are:

Yahoo | May 14, 2020

Edited Transcript of ISR earnings conference call or presentation 12-May-20 8:30pm GMT

Q1 2020 IsoRay Inc Earnings Call

Yahoo | May 13, 2020

IsoRay (ISR) Reports Q3 Loss, Tops Revenue Estimates

IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and 4.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 12, 2020

Read More 'ISR' Stories Here

ISR Price Returns

1-mo 1.04%
3-mo -3.21%
6-mo 16.67%
1-year 64.32%
3-year 27.27%
5-year -55.97%
YTD 12.11%
2019 108.13%
2018 -24.81%
2017 -31.21%
2016 -38.30%
2015 -35.62%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9499 seconds.